Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis

NCT01928433 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 225

Last updated 2017-06-20

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to evaluate the microbiological and clinical outcome of treatment with finafloxacin for 5 days versus finafloxacin for 10 days versus ciprofloxacin for 10 days as a reference comparator.

Finafloxacin shows increased activity in an acidic environment which is associated with indications such as uUTI and cUTI. Given the acidic pH of urine and concentration of finafloxacin excreted via the urinary tract in humans it should be proven if the finafloxacin treatments offer significant advantages over the currently available treatments for UTI.

Conditions

Interventions

DRUG

Finafloxacin 800 mg i.v. once daily

Infused over 60 mins \[i.v. pump\]) for at least 3 days.

DRUG

Finafloxacin placebo i.v. once daily

Infused over 60 mins \[i.v. pump\]) for at least 3 days.

DRUG

Finafloxacin 800 mg tablets once daily

Administered as four 200 mg tablets

DRUG

Finafloxacin placebo tablets once daily

Administered as four tablets

DRUG

Ciprofloxacin 400 mg i.v. twice daily

Infused over approximately 60 mins \[i.v. pump\]) for at least 3 days

DRUG

Ciprofloxacin placebo i.v. twice daily

Infused over approximately 60 mins \[i.v. pump\]) for at least 3 days

DRUG

Ciprofloxacin 500 mg oral twice daily

Administered as two 250 mg capsules.

DRUG

Ciprofloxacin placebo oral twice daily

Administered as two capsules.

Sponsors & Collaborators

  • MerLion Pharmaceuticals GmbH

    lead INDUSTRY

Principal Investigators

  • Florian Wagenlehner, Prof. · Germany: University Hospital Giessen and Marburg, Department of Urology

  • Michal Nowicki, Prof. · Poland: Medical University Lodz, Department of Nephrology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2014-06-30
Completion
2015-10-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01928433 on ClinicalTrials.gov